<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27249416</article-id><article-id pub-id-type="pmc">4889106</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0156381</article-id><article-id pub-id-type="publisher-id">PONE-D-16-10738</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Nephrology</subject><subj-group><subject>Chronic Kidney Disease</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Physical Chemistry</subject><subj-group><subject>Ions</subject><subj-group><subject>Anions</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Demography</subject><subj-group><subject>Death Rates</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Population Biology</subject><subj-group><subject>Population Metrics</subject><subj-group><subject>Death Rates</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Toxicology</subject><subj-group><subject>Toxic Agents</subject><subj-group><subject>Toxins</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Toxicology</subject><subj-group><subject>Toxic Agents</subject><subj-group><subject>Toxins</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Hematology</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Biomarkers</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Compounds</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Urea</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Organic Chemistry</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Urea</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Renal Physiology</subject><subj-group><subject>Glomerular Filtration Rate</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Renal Physiology</subject><subj-group><subject>Glomerular Filtration Rate</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Serum Anion Gap Predicts All-Cause Mortality in Patients with Advanced Chronic Kidney Disease: A Retrospective Analysis of a Randomized Controlled Study</article-title><alt-title alt-title-type="running-head">Anion Gap and Mortality in Advanced CKD Patients</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Sung Woo</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Sejoong</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Na</surname><given-names>Ki Young</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cha</surname><given-names>Ran-hui</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kang</surname><given-names>Shin Wook</given-names></name><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Cheol Whee</given-names></name><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cha</surname><given-names>Dae Ryong</given-names></name><xref ref-type="aff" rid="aff007"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Sung Gyun</given-names></name><xref ref-type="aff" rid="aff008"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yoon</surname><given-names>Sun Ae</given-names></name><xref ref-type="aff" rid="aff009"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Sang Youb</given-names></name><xref ref-type="aff" rid="aff010"><sup>10</sup></xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Jung Hwan</given-names></name><xref ref-type="aff" rid="aff011"><sup>11</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Jae Hyun</given-names></name><xref ref-type="aff" rid="aff012"><sup>12</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lim</surname><given-names>Chun Soo</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref><xref ref-type="aff" rid="aff013"><sup>13</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Yon Su</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref><xref ref-type="aff" rid="aff014"><sup>14</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Department of Internal Medicine, Eulji General Hospital, Seoul, 01830, Korea</addr-line></aff><aff id="aff002"><label>2</label><addr-line>Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, 13620, Korea</addr-line></aff><aff id="aff003"><label>3</label><addr-line>Department of Internal Medicine, Seoul National University College of Medicine, Seoul, 03080, Korea</addr-line></aff><aff id="aff004"><label>4</label><addr-line>Department of Internal Medicine, National Medical Center, Seoul, 04564, Korea</addr-line></aff><aff id="aff005"><label>5</label><addr-line>Department of Internal Medicine, Yonsei University College of Medicine 03722, Seoul, Korea</addr-line></aff><aff id="aff006"><label>6</label><addr-line>Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, 06591, Korea</addr-line></aff><aff id="aff007"><label>7</label><addr-line>Department of Internal Medicine, Korea University Ansan-Hospital, Korea University, Ansan, Gyeonggi-do, 15355, Korea</addr-line></aff><aff id="aff008"><label>8</label><addr-line>Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, 14068, Korea</addr-line></aff><aff id="aff009"><label>9</label><addr-line>Department of Internal Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Uijeongbu, Gyeonggi-do, 11765, Korea</addr-line></aff><aff id="aff010"><label>10</label><addr-line>Department of Internal Medicine, Inje University Ilsan-Paik Hospital, Goyang, Gyeonggi-do, 10380, Korea</addr-line></aff><aff id="aff011"><label>11</label><addr-line>Department of Internal Medicine, Konkuk University School of Medicine, Seoul, 05030, Korea</addr-line></aff><aff id="aff012"><label>12</label><addr-line>Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University of Medicine and Science, Incheon, 21565, Korea</addr-line></aff><aff id="aff013"><label>13</label><addr-line>Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, 08708, Korea</addr-line></aff><aff id="aff014"><label>14</label><addr-line>Kidney Research Institute, Seoul National University, Seoul, 03080, Korea</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Cravedi</surname><given-names>Paolo</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"></xref></contrib></contrib-group><aff id="edit1"><addr-line>Ichan School of Medicine at Mount Sinai, UNITED STATES</addr-line></aff><author-notes><fn fn-type="conflict" id="coi001"><p><bold>Competing Interests: </bold>The authors of this manuscript have read the journal's policy and have the following competing interests: The authors received funding from CJ HealthCare Corporation and Kureha Corporation, both commercial companies, for this study. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: SWL SK KYN CSL YSK. Performed the experiments: SWL R-HC SWK CWP DRC. Analyzed the data: SWL SGK SAY SYH JHP JHC. Contributed reagents/materials/analysis tools: R-HC YSK. Wrote the paper: SWL SK.</p></fn><corresp id="cor001">* E-mail: <email>sejoong2@snu.ac.kr</email></corresp></author-notes><pub-date pub-type="epub"><day>1</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>11</volume><issue>6</issue><elocation-id>e0156381</elocation-id><history><date date-type="received"><day>28</day><month>3</month><year>2016</year></date><date date-type="accepted"><day>15</day><month>5</month><year>2016</year></date></history><permissions><copyright-statement>© 2016 Lee et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Lee et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0156381.pdf"></self-uri><abstract><sec id="sec001"><title><offsets xml_i="12776" xml_f="12801" txt_i="11" txt_f="36">Background and Objectives</offsets></title><p><offsets xml_i="12812" xml_f="12985" txt_i="37" txt_f="210">Cardiovascular outcomes and mortality rates are poor in advanced chronic kidney disease (CKD) patients. Novel risk factors related to clinical outcomes should be identified.</offsets></p></sec><sec id="sec002"><title><offsets xml_i="13019" xml_f="13026" txt_i="212" txt_f="219">Methods</offsets></title><p><offsets xml_i="13037" xml_f="13219" txt_i="220" txt_f="399">A retrospective analysis of data from a randomized controlled study was performed in 440 CKD patients aged &gt; 18 years, with estimated glomerular filtration rate 15–60 mL/min/1.73m</offsets><sup><offsets xml_i="13224" xml_f="13225" txt_i="399" txt_f="400">2</offsets></sup><offsets xml_i="13231" xml_f="13378" txt_i="400" txt_f="547">. Clinical data were available, and the albumin-adjusted serum anion gap (A-SAG) could be calculated. The outcome analyzed was all-cause mortality.</offsets></p></sec><sec id="sec003"><title><offsets xml_i="13412" xml_f="13419" txt_i="549" txt_f="556">Results</offsets></title><p><offsets xml_i="13430" xml_f="13736" txt_i="557" txt_f="863">Of 440 participants, the median (interquartile range, IQR) follow-up duration was 5.1 (3.0–5.5) years. During the follow-up duration, 29 participants died (all-cause mortality 6.6%). The area under the receiver operating characteristic curve of A-SAG for all-cause mortality was 0.616 (95% CI 0.520–0.712, </offsets><italic><offsets xml_i="13744" xml_f="13745" txt_i="863" txt_f="864">P</offsets></italic><offsets xml_i="13754" xml_f="14055" txt_i="864" txt_f="1165"> = 0.037). The best threshold of A-SAG for all-cause mortality was 9.48 mmol/L, with sensitivity 0.793 and specificity 0.431. After adjusting for confounders, A-SAG above 9.48 mmol/L was independently associated with increased risk of all-cause mortality, with hazard ratio 2.968 (95% CI 1.143–7.708, </offsets><italic><offsets xml_i="14063" xml_f="14064" txt_i="1165" txt_f="1166">P</offsets></italic><offsets xml_i="14073" xml_f="14203" txt_i="1166" txt_f="1296"> = 0.025). In our study, serum levels of beta-2 microglobulin and blood urea nitrogen (BUN) were positively associated with A-SAG.</offsets></p></sec><sec id="sec004"><title><offsets xml_i="14237" xml_f="14248" txt_i="1298" txt_f="1309">Conclusions</offsets></title><p><offsets xml_i="14259" xml_f="14474" txt_i="1310" txt_f="1525">A-SAG is an independent risk factor for all-cause mortality in advanced CKD patients. The positive correlation between A-SAG and serum beta-2 microglobulin or BUN might be a potential reason. Future study is needed.</offsets></p></sec><sec id="sec005"><title><offsets xml_i="14508" xml_f="14526" txt_i="1527" txt_f="1545">Trial Registration</offsets></title><p><offsets xml_i="14537" xml_f="14556" txt_i="1546" txt_f="1565">Clinicaltrials.gov </offsets><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00860431"><offsets xml_i="14647" xml_f="14659" txt_i="1565" txt_f="1577">NCT 00860431</offsets></ext-link></p></sec></abstract><funding-group><award-group id="award001"><funding-source><institution>CJ HealthCare Corporation and Kureha Corporation</institution></funding-source></award-group><funding-statement>Commercial companies CJ HealthCare Corporation and Kureha Corporation provided funding for this study, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="4"></fig-count><table-count count="2"></table-count><page-count count="12"></page-count></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper.</p></notes></front><body><sec sec-type="intro" id="sec006"><title><offsets xml_i="15634" xml_f="15646" txt_i="1586" txt_f="1598">Introduction</offsets></title><p><offsets xml_i="15657" xml_f="15769" txt_i="1599" txt_f="1711">The prevalence of chronic kidney disease (CKD) ranges between approximately 7% - 10% in the general population [</offsets><xref rid="pone.0156381.ref001" ref-type="bibr"><offsets xml_i="15817" xml_f="15818" txt_i="1711" txt_f="1712">1</offsets></xref><offsets xml_i="15825" xml_f="16016" txt_i="1712" txt_f="1903">]. CKD is dangerous because it is independently associated with mortality even after adjusting for various chronic conditions such as hypertension, diabetes and major adverse cardiac events [</offsets><xref rid="pone.0156381.ref002" ref-type="bibr"><offsets xml_i="16064" xml_f="16065" txt_i="1903" txt_f="1904">2</offsets></xref><offsets xml_i="16072" xml_f="16074" txt_i="1904" txt_f="1906">, </offsets><xref rid="pone.0156381.ref003" ref-type="bibr"><offsets xml_i="16122" xml_f="16123" txt_i="1906" txt_f="1907">3</offsets></xref><offsets xml_i="16130" xml_f="16266" txt_i="1907" txt_f="2043">]. Therefore, it is of utmost importance to identify biomarkers predicting poor outcomes in CKD. Several candidates have been proposed [</offsets><xref rid="pone.0156381.ref004" ref-type="bibr"><offsets xml_i="16314" xml_f="16315" txt_i="2043" txt_f="2044">4</offsets></xref><offsets xml_i="16322" xml_f="16460" txt_i="2044" txt_f="2182">], but, these biomarkers are not always applicable in routine practice. Thus, novel and easily accessible biomarkers should be identified.</offsets></p><p><offsets xml_i="16467" xml_f="16696" txt_i="2183" txt_f="2412">The serum anion gap (SAG) is easily calculated from the electrolytes. Along with differential diagnosis of acid-base disorders, it can be used to assess laboratory quality control and diagnose intoxications and paraproteinemias [</offsets><xref rid="pone.0156381.ref005" ref-type="bibr"><offsets xml_i="16744" xml_f="16745" txt_i="2412" txt_f="2413">5</offsets></xref><offsets xml_i="16752" xml_f="17083" txt_i="2413" txt_f="2744">]. However, recent studies have suggested the expanded use of SAG as a biomarker. Farwell and colleagues analyzed the data from the National Health and Nutrition Examination Survey (NHANES). They proposed that increased SAG is associated with blood pressure, insulin resistance, and inflammation in the healthy general population [</offsets><xref rid="pone.0156381.ref006" ref-type="bibr"><offsets xml_i="17131" xml_f="17132" txt_i="2744" txt_f="2745">6</offsets></xref><offsets xml_i="17139" xml_f="17140" txt_i="2745" txt_f="2746">–</offsets><xref rid="pone.0156381.ref008" ref-type="bibr"><offsets xml_i="17188" xml_f="17189" txt_i="2746" txt_f="2747">8</offsets></xref><offsets xml_i="17196" xml_f="17289" txt_i="2747" txt_f="2840">]. Moreover, SAG is an independent risk factor for mortality in acute myocardial infarction [</offsets><xref rid="pone.0156381.ref009" ref-type="bibr"><offsets xml_i="17337" xml_f="17338" txt_i="2840" txt_f="2841">9</offsets></xref><offsets xml_i="17345" xml_f="17366" txt_i="2841" txt_f="2862">], critical illness [</offsets><xref rid="pone.0156381.ref010" ref-type="bibr"><offsets xml_i="17414" xml_f="17416" txt_i="2862" txt_f="2864">10</offsets></xref><offsets xml_i="17423" xml_f="17471" txt_i="2864" txt_f="2912">], and an otherwise healthy elderly population [</offsets><xref rid="pone.0156381.ref011" ref-type="bibr"><offsets xml_i="17519" xml_f="17521" txt_i="2912" txt_f="2914">11</offsets></xref><offsets xml_i="17528" xml_f="17530" txt_i="2914" txt_f="2916">].</offsets></p><p><offsets xml_i="17537" xml_f="17608" txt_i="2917" txt_f="2988">SAG is elevated and related to mortality even in early kidney disease [</offsets><xref rid="pone.0156381.ref012" ref-type="bibr"><offsets xml_i="17656" xml_f="17658" txt_i="2988" txt_f="2990">12</offsets></xref><offsets xml_i="17665" xml_f="17717" txt_i="2990" txt_f="3042">], and high SAG is associated with CKD progression [</offsets><xref rid="pone.0156381.ref013" ref-type="bibr"><offsets xml_i="17765" xml_f="17767" txt_i="3042" txt_f="3044">13</offsets></xref><offsets xml_i="17774" xml_f="18083" txt_i="3044" txt_f="3353">]. Therefore, we hypothesized that SAG might predict mortality in advanced CKD patients. We performed the current study to identify whether SAG was associated with all-cause mortality using data from a prospective randomized controlled study, KSTAR (Kremezin STudy Against Renal disease progression in Korea).</offsets></p></sec><sec sec-type="materials|methods" id="sec007"><title><offsets xml_i="18146" xml_f="18166" txt_i="3355" txt_f="3375">Material and Methods</offsets></title><sec id="sec008"><title><offsets xml_i="18198" xml_f="18214" txt_i="3376" txt_f="3392">Study population</offsets></title><p><offsets xml_i="18225" xml_f="18390" txt_i="3393" txt_f="3558">KSTAR was a prospective, 11-center, randomized, open–label, controlled study (Clinicaltrials.gov: NCT 00860431). The detailed study protocol is described elsewhere [</offsets><xref rid="pone.0156381.ref014" ref-type="bibr"><offsets xml_i="18438" xml_f="18440" txt_i="3558" txt_f="3560">14</offsets></xref><offsets xml_i="18447" xml_f="18690" txt_i="3560" txt_f="3803">]. In brief, participants with advanced CKD recruited from March 2009 to August 2010 were followed up for 36 months. Those aged ≥ 18 years, with estimated glomerular filtration rate (eGFR) by the Cockcroft-Gault equation of 15–59 mL/min/1.73 m</offsets><sup><offsets xml_i="18695" xml_f="18696" txt_i="3803" txt_f="3804">2</offsets></sup><offsets xml_i="18702" xml_f="18788" txt_i="3804" txt_f="3890">, and who had a measured or expected decline of kidney function of ≥ 2.5 mL/min/1.73 m</offsets><sup><offsets xml_i="18793" xml_f="18794" txt_i="3890" txt_f="3891">2</offsets></sup><offsets xml_i="18800" xml_f="18836" txt_i="3891" txt_f="3927"> for six months or ≥ 5 mL/min/1.73 m</offsets><sup><offsets xml_i="18841" xml_f="18842" txt_i="3927" txt_f="3928">2</offsets></sup><offsets xml_i="18848" xml_f="20171" txt_i="3928" txt_f="5251"> for 12 months, were included in the original study. The study protocol was approved by the institutional review boards of the participating centers, and the study was performed in compliance with the principles of the Declaration of Helsinki. In addition to the original data, we retrospectively collected data on the status of survival as of July 2015 through review of medical records. The retrospective expansion of the follow-up duration was also approved by the institutional review boards (IRBs) of the participating centers: Seoul National University Bundang Hospital (B-0812/066-006), Seoul National University Bundang Hospital (0810-009-259), Seoul National University Boramae Medical Center (06-2009-7), Yonsei University Hospital (4-2008-0586), Korea University Ansan-Hospital(AS0884), Hallym University Sacred Heart Hospital (2009-I004), Inje University Ilsan-Paik Hospital (IB-0811-076), Konkuk University Hospital (KUH1010125), and Gachon University Gil Medical Center (GIRBA2010). The need for informed consent for the retrospective expansion was waived by the IRBs of participating hospitals because the study did not infringe on patient privacy or health status. Patient records and information were anonymized and de-identified prior to analysis. Of 579 participants, 440 were eligible for the analysis (</offsets><xref ref-type="fig" rid="pone.0156381.g001"><offsets xml_i="20216" xml_f="20221" txt_i="5251" txt_f="5256">Fig 1</offsets></xref><offsets xml_i="20228" xml_f="20230" txt_i="5256" txt_f="5258">).</offsets></p><fig id="pone.0156381.g001" orientation="portrait" position="float"><object-id pub-id-type="doi"><offsets xml_i="20331" xml_f="20364" txt_i="5259" txt_f="5292">10.1371/journal.pone.0156381.g001</offsets></object-id><label><offsets xml_i="20383" xml_f="20388" txt_i="5292" txt_f="5297">Fig 1</offsets></label><caption><title><offsets xml_i="20412" xml_f="20440" txt_i="5297" txt_f="5325">Patient selection algorithm.</offsets></title><p><offsets xml_i="20451" xml_f="20493" txt_i="5326" txt_f="5368">ITT, intention to treat; PP, per protocol.</offsets></p></caption><graphic xlink:href="pone.0156381.g001"></graphic></fig></sec><sec id="sec009"><title><offsets xml_i="20593" xml_f="20620" txt_i="5370" txt_f="5397">Definition and measurements</offsets></title><p><offsets xml_i="20631" xml_f="20722" txt_i="5398" txt_f="5489">The eGFR was calculated by the Chronic Kidney Disease EPIdemiology collaboration equation [</offsets><xref rid="pone.0156381.ref015" ref-type="bibr"><offsets xml_i="20770" xml_f="20772" txt_i="5489" txt_f="5491">15</offsets></xref><offsets xml_i="20779" xml_f="20911" txt_i="5491" txt_f="5623">]. The SAG was defined using the following equation: SAG (initial) = serum sodium [mEq/L] − (serum chloride [mEq/L] + serum total CO</offsets><sub><offsets xml_i="20916" xml_f="20917" txt_i="5623" txt_f="5624">2</offsets></sub><offsets xml_i="20923" xml_f="21100" txt_i="5624" txt_f="5801"> [mEq/L]). Since approximately 80% of SAG is due to the sum of anionic charges on blood proteins, and albumin is the most abundant, hypoalbuminemia could falsely lower the SAG [</offsets><xref rid="pone.0156381.ref005" ref-type="bibr"><offsets xml_i="21148" xml_f="21149" txt_i="5801" txt_f="5802">5</offsets></xref><offsets xml_i="21156" xml_f="21318" txt_i="5802" txt_f="5964">]. Thus SAG needed to be adjusted for serum albumin using the following equation: albumin-adjusted SAG (A-SAG) = SAG (initial) + 2.5 × (4 –serum albumin [g/dL]) [</offsets><xref rid="pone.0156381.ref016" ref-type="bibr"><offsets xml_i="21366" xml_f="21368" txt_i="5964" txt_f="5966">16</offsets></xref><offsets xml_i="21375" xml_f="21517" txt_i="5966" txt_f="6108">]. Serum total indoxyl sulfate (IS) was measured by a high performance liquid chromatography fluorescence detector (Agilent 1100 series, USA).</offsets></p></sec><sec id="sec010"><title><offsets xml_i="21551" xml_f="21571" txt_i="6110" txt_f="6130">Statistical analysis</offsets></title><p><offsets xml_i="21582" xml_f="21735" txt_i="6131" txt_f="6284">Values were expressed as mean ± standard deviation (SD) for continuous variables and percentage for categorical variables. Differences were evaluated by </offsets><italic><offsets xml_i="21743" xml_f="21754" txt_i="6284" txt_f="6295">Student`s t</offsets></italic><offsets xml_i="21763" xml_f="22054" txt_i="6295" txt_f="6586">-test for continuous variables and the chi-square test for categorical variables. Normality was assessed using a Q-Q plot. If continuous variables were not normally distributed, values were expressed as median (interquartile range, IQR), and the difference was evaluated by the Mann-Whitney </offsets><italic><offsets xml_i="22062" xml_f="22063" txt_i="6586" txt_f="6587">U</offsets></italic><offsets xml_i="22072" xml_f="22392" txt_i="6587" txt_f="6907"> test. The survival curve was evaluated by the Kaplan-Meier method. To adjust for confounding effects among variables, we performed Cox-proportional hazard regression analysis. The assumption of proportional hazard was verified by a log minus log plot. The integrated variables were known risk factors or variables with </offsets><italic><offsets xml_i="22400" xml_f="22401" txt_i="6907" txt_f="6908">P</offsets></italic><offsets xml_i="22410" xml_f="22601" txt_i="6908" txt_f="7096"> &lt; 0.05 in univariate analysis. For linearity assessment between continuous variables and all-cause mortality, we fitted restricted cubic splines using R Version 3.03 (R Core Team, 2014) [</offsets><xref rid="pone.0156381.ref017" ref-type="bibr"><offsets xml_i="22649" xml_f="22651" txt_i="7096" txt_f="7098">17</offsets></xref><offsets xml_i="22658" xml_f="22680" txt_i="7098" txt_f="7120">] with “rms” package [</offsets><xref rid="pone.0156381.ref018" ref-type="bibr"><offsets xml_i="22728" xml_f="22730" txt_i="7120" txt_f="7122">18</offsets></xref><offsets xml_i="22737" xml_f="22781" txt_i="7122" txt_f="7166">]. Since the restricted cubic spline curve (</offsets><xref ref-type="fig" rid="pone.0156381.g002"><offsets xml_i="22826" xml_f="22831" txt_i="7166" txt_f="7171">Fig 2</offsets></xref><offsets xml_i="22838" xml_f="22911" txt_i="7171" txt_f="7244">) and multivariate Cox-proportional hazard regression of A-SAG quintile (</offsets><xref ref-type="supplementary-material" rid="pone.0156381.s001"><offsets xml_i="22975" xml_f="22983" txt_i="7244" txt_f="7252">S1 Table</offsets></xref><offsets xml_i="22990" xml_f="23293" txt_i="7252" txt_f="7552">) revealed a non-linear association between A-SAG and all-cause mortality, all participants were divided into two groups of ≥ vs. &lt; the threshold of A-SAG calculated from the area under the receiver operating characteristic curve (AUROC) using R Version 3.03 (R Core Team, 2014) with “pROC” package [</offsets><xref rid="pone.0156381.ref019" ref-type="bibr"><offsets xml_i="23341" xml_f="23343" txt_i="7552" txt_f="7554">19</offsets></xref><offsets xml_i="23350" xml_f="23598" txt_i="7554" txt_f="7802">]. The best threshold was calculated by obtaining the best Youden index (sensitivity + specificity—1). For comparison of mean and linear regression of serum total IS, logarithmic transformation was performed, since it was non-normally distributed. </offsets><italic><offsets xml_i="23606" xml_f="23607" txt_i="7802" txt_f="7803">P</offsets></italic><offsets xml_i="23616" xml_f="23800" txt_i="7803" txt_f="7984"> &lt; 0.05 was considered to have statistical significance. All analysis unless otherwise specified was performed using SPSS Version 22 (IBM Corp. released 2013, Armonk, NY: IBM Corp).</offsets></p><fig id="pone.0156381.g002" orientation="portrait" position="float"><object-id pub-id-type="doi"><offsets xml_i="23901" xml_f="23934" txt_i="7985" txt_f="8018">10.1371/journal.pone.0156381.g002</offsets></object-id><label><offsets xml_i="23953" xml_f="23958" txt_i="8018" txt_f="8023">Fig 2</offsets></label><caption><title><offsets xml_i="23982" xml_f="24080" txt_i="8023" txt_f="8121">Restricted cubic spline curve of albumin-adjusted serum anion gap (A-SAG) for all-cause mortality.</offsets></title><p><offsets xml_i="24091" xml_f="24176" txt_i="8122" txt_f="8207">As A-SAG increased, the log hazard of all-cause mortality increased, but nonlinearly.</offsets></p></caption><graphic xlink:href="pone.0156381.g002"></graphic></fig></sec></sec><sec sec-type="results" id="sec011"><title><offsets xml_i="24301" xml_f="24308" txt_i="8210" txt_f="8217">Results</offsets></title><p><offsets xml_i="24319" xml_f="24517" txt_i="8218" txt_f="8416">Of 440 participants, the median (IQR) follow-up duration was 5.1 (3.0–5.5) years. At baseline, mean age was 56.8 ± 13.1 years and men were 294/440 (66.8%). The mean eGFR was 23.2 ± 6.8 mL/min/1.73 m</offsets><sup><offsets xml_i="24522" xml_f="24523" txt_i="8416" txt_f="8417">2</offsets></sup><offsets xml_i="24529" xml_f="24765" txt_i="8417" txt_f="8653"> and median urine protein creatinine ratio (UPCR) (IQR) was 1.2 (0.4–2.9) g/g. The proportion of diabetic nephropathy as a cause of CKD was 204/440 (46.4%). During the follow-up duration, 29 participants died (all-cause mortality 6.6%).</offsets></p><p><offsets xml_i="24772" xml_f="24867" txt_i="8654" txt_f="8749">We evaluated several cut-points of A-SAG and found only 9.3 mmol/L, the cut-point between the 2</offsets><sup><offsets xml_i="24872" xml_f="24874" txt_i="8749" txt_f="8751">nd</offsets></sup><offsets xml_i="24880" xml_f="24886" txt_i="8751" txt_f="8757"> and 3</offsets><sup><offsets xml_i="24891" xml_f="24893" txt_i="8757" txt_f="8759">rd</offsets></sup><offsets xml_i="24899" xml_f="24964" txt_i="8759" txt_f="8824"> quintile was significantly associated with all-cause mortality (</offsets><xref ref-type="supplementary-material" rid="pone.0156381.s002"><offsets xml_i="25028" xml_f="25036" txt_i="8824" txt_f="8832">S2 Table</offsets></xref><offsets xml_i="25043" xml_f="25174" txt_i="8832" txt_f="8963">). In discrimination analysis, the AUROC of A-SAG for the all-cause mortality was 0.616 (95% confidence interval [CI] 0.520–0.712, </offsets><italic><offsets xml_i="25182" xml_f="25183" txt_i="8963" txt_f="8964">P</offsets></italic><offsets xml_i="25192" xml_f="25423" txt_i="8964" txt_f="9195"> = 0.037). The best threshold of A-SAG for all-cause mortality was 9.48 mmol/L, with sensitivity 0.793 and specificity 0.431. We compared the baseline characteristics of the participants according to the status of A-SAG threshold (</offsets><xref ref-type="table" rid="pone.0156381.t001"><offsets xml_i="25470" xml_f="25477" txt_i="9195" txt_f="9202">Table 1</offsets></xref><offsets xml_i="25484" xml_f="26180" txt_i="9202" txt_f="9883">). The means of A-SAG in ≥ and &lt; 9.48 mmol/L of A-SAG groups were 11.5 ± 1.9 mmol/L and 7.8 ± 1.4 mmol/L, respectively. The A-SAG ≥ 9.48 mmol/L group showed higher male proportion than the A-SAG &lt; 9.48 mmol/L group. Although serum level of inorganic phosphorus was not different between the two A-SAG groups, the serum levels of potassium and chloride were significantly lower in A-SAG ≥ 9.48 mmol/L group than A-SAG &lt; 9.48 mmol/L group. Participants with A-SAG ≥ 9.48 mmol/L showed lower eGFR and higher blood urea nitrogen (BUN) than those with A-SAG &lt; 9.48 mmol/L. The all-cause mortality of ≥ and &lt; 9.48 mmol/L of A-SAG groups was 23/257 (8.9%) and 6/183 (3.3%), respectively (</offsets><italic><offsets xml_i="26188" xml_f="26189" txt_i="9883" txt_f="9884">P</offsets></italic><offsets xml_i="26198" xml_f="26250" txt_i="9884" txt_f="9936"> = 0.019). In Kaplan-Meier survival curve analysis (</offsets><xref ref-type="fig" rid="pone.0156381.g003"><offsets xml_i="26295" xml_f="26300" txt_i="9936" txt_f="9941">Fig 3</offsets></xref><offsets xml_i="26307" xml_f="26409" txt_i="9941" txt_f="10040">), the A-SAG ≥ 9.48 mmol/L group showed poorer patient survival than the A-SAG &lt; 9.48 mmol/L group.</offsets></p><fig id="pone.0156381.g003" orientation="portrait" position="float"><object-id pub-id-type="doi"><offsets xml_i="26510" xml_f="26543" txt_i="10041" txt_f="10074">10.1371/journal.pone.0156381.g003</offsets></object-id><label><offsets xml_i="26562" xml_f="26567" txt_i="10074" txt_f="10079">Fig 3</offsets></label><caption><title><offsets xml_i="26591" xml_f="26684" txt_i="10079" txt_f="10172">Kaplan-Meier survival curve according to the albumin-adjusted serum anion gap (A-SAG) status.</offsets></title><p><offsets xml_i="26695" xml_f="26824" txt_i="10173" txt_f="10299">Mean (95% CI) survivals of &lt; and ≥ 9.48 mmol/L of A-SAG groups were 6.1 (6.0–6.2) years and 5.9 (5.7–6.1) years, respectively.</offsets></p></caption><graphic xlink:href="pone.0156381.g003"></graphic></fig><table-wrap id="pone.0156381.t001" orientation="portrait" position="float"><object-id pub-id-type="doi"><offsets xml_i="26998" xml_f="27031" txt_i="10300" txt_f="10333">10.1371/journal.pone.0156381.t001</offsets></object-id><label><offsets xml_i="27050" xml_f="27057" txt_i="10333" txt_f="10340">Table 1</offsets></label><caption><title><offsets xml_i="27081" xml_f="27149" txt_i="10340" txt_f="10408">Baseline characteristics according to the status of A-SAG threshold.</offsets></title></caption><alternatives><graphic id="pone.0156381.t001g" xlink:href="pone.0156381.t001"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="justify" rowspan="1" colspan="1"></th><th align="justify" rowspan="1" colspan="1"><offsets xml_i="27622" xml_f="27654" txt_i="10409" txt_f="10438">A-SAG &lt; 9.48 mmol/L (n = 183)</offsets></th><th align="justify" rowspan="1" colspan="1"><offsets xml_i="27703" xml_f="27732" txt_i="10438" txt_f="10467">A-SAG ≥ 9.48 mmol/L (n = 257)</offsets></th><th align="center" rowspan="1" colspan="1"><italic><offsets xml_i="27788" xml_f="27789" txt_i="10467" txt_f="10468">P</offsets></italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="27868" xml_f="27879" txt_i="10468" txt_f="10479">Age (years)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="27927" xml_f="27938" txt_i="10480" txt_f="10491">56.0 ± 13.1</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="27986" xml_f="27997" txt_i="10492" txt_f="10503">57.3 ± 13.2</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="28045" xml_f="28050" txt_i="10504" txt_f="10509">0.297</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="28105" xml_f="28113" txt_i="10510" txt_f="10518">Male sex</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="28161" xml_f="28175" txt_i="10519" txt_f="10533">132/183 (72.1)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="28223" xml_f="28237" txt_i="10534" txt_f="10548">162/257 (63.0)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="28285" xml_f="28290" txt_i="10549" txt_f="10554">0.046</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="28345" xml_f="28365" txt_i="10555" txt_f="10575">Diabetic nephropathy</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="28413" xml_f="28426" txt_i="10576" txt_f="10589">83/183 (45.4)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="28474" xml_f="28488" txt_i="10590" txt_f="10604">121/257 (47.1)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="28536" xml_f="28541" txt_i="10605" txt_f="10610">0.720</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="28596" xml_f="28614" txt_i="10611" txt_f="10629">Systolic BP (mmHg)</offsets><xref ref-type="table-fn" rid="t001fn003"><sup><offsets xml_i="28661" xml_f="28662" txt_i="10629" txt_f="10630">b</offsets></sup></xref></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="28723" xml_f="28735" txt_i="10631" txt_f="10643">131.0 ± 15.0</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="28783" xml_f="28795" txt_i="10644" txt_f="10656">130.9 ± 14.1</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="28843" xml_f="28848" txt_i="10657" txt_f="10662">0.931</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="28903" xml_f="28921" txt_i="10663" txt_f="10681">eGFR (mL/min/1.73m</offsets><sup><offsets xml_i="28926" xml_f="28927" txt_i="10681" txt_f="10682">2</offsets></sup><offsets xml_i="28933" xml_f="28934" txt_i="10682" txt_f="10683">)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="28982" xml_f="28992" txt_i="10684" txt_f="10694">24.2 ± 6.8</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="29040" xml_f="29050" txt_i="10695" txt_f="10705">22.5 ± 6.7</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="29098" xml_f="29103" txt_i="10706" txt_f="10711">0.012</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="29158" xml_f="29186" txt_i="10712" txt_f="10740">Blood urea nitrogen (mmol/L)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="29234" xml_f="29244" txt_i="10741" txt_f="10751">14.3 ± 4.1</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="29292" xml_f="29302" txt_i="10752" txt_f="10762">15.9 ± 5.6</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="29350" xml_f="29359" txt_i="10763" txt_f="10769">&lt;0.001</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="29414" xml_f="29433" txt_i="10770" txt_f="10789">Creatinine (μmol/L)</offsets><xref ref-type="table-fn" rid="t001fn002"><sup><offsets xml_i="29480" xml_f="29481" txt_i="10789" txt_f="10790">a</offsets></sup></xref></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="29542" xml_f="29561" txt_i="10791" txt_f="10810">229.8 (203.3–282.9)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="29609" xml_f="29628" txt_i="10811" txt_f="10830">238.7 (203.3–291.7)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="29676" xml_f="29681" txt_i="10831" txt_f="10836">0.157</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="29736" xml_f="29772" txt_i="10837" txt_f="10873">Urine protein creatinine ratio (g/g)</offsets><xref ref-type="table-fn" rid="t001fn002"><sup><offsets xml_i="29819" xml_f="29820" txt_i="10873" txt_f="10874">a</offsets></sup></xref><sup><offsets xml_i="29838" xml_f="29839" txt_i="10874" txt_f="10875">,</offsets></sup><xref ref-type="table-fn" rid="t001fn003"><sup><offsets xml_i="29892" xml_f="29893" txt_i="10875" txt_f="10876">b</offsets></sup></xref></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="29954" xml_f="29967" txt_i="10877" txt_f="10890">1.1 (0.4–2.9)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="30015" xml_f="30028" txt_i="10891" txt_f="10904">1.3 (0.5–2.9)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="30076" xml_f="30081" txt_i="10905" txt_f="10910">0.315</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="30136" xml_f="30158" txt_i="10911" txt_f="10933">Total calcium (mmol/L)</offsets><xref ref-type="table-fn" rid="t001fn003"><sup><offsets xml_i="30205" xml_f="30206" txt_i="10933" txt_f="10934">b</offsets></sup></xref></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="30267" xml_f="30276" txt_i="10935" txt_f="10944">2.2 ± 0.1</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="30324" xml_f="30333" txt_i="10945" txt_f="10954">2.2 ± 0.2</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="30381" xml_f="30386" txt_i="10955" txt_f="10960">0.466</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="30441" xml_f="30470" txt_i="10961" txt_f="10990">Inorganic phosphorus (mmol/L)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="30518" xml_f="30527" txt_i="10991" txt_f="11000">1.2 ± 0.2</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="30575" xml_f="30584" txt_i="11001" txt_f="11010">1.3 ± 0.3</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="30632" xml_f="30637" txt_i="11011" txt_f="11016">0.087</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="30692" xml_f="30714" txt_i="11017" txt_f="11039">Serum glucose (mmol/L)</offsets><xref ref-type="table-fn" rid="t001fn003"><sup><offsets xml_i="30761" xml_f="30762" txt_i="11039" txt_f="11040">b</offsets></sup></xref></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="30823" xml_f="30832" txt_i="11041" txt_f="11050">6.3 ± 2.2</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="30880" xml_f="30889" txt_i="11051" txt_f="11060">6.6 ± 2.8</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="30937" xml_f="30942" txt_i="11061" txt_f="11066">0.287</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="30997" xml_f="31016" txt_i="11067" txt_f="11086">Serum albumin (g/L)</offsets><xref ref-type="table-fn" rid="t001fn002"><sup><offsets xml_i="31063" xml_f="31064" txt_i="11086" txt_f="11087">a</offsets></sup></xref></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="31125" xml_f="31141" txt_i="11088" txt_f="11104">41.0 (39.0–44.0)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="31189" xml_f="31205" txt_i="11105" txt_f="11121">40.0 (38.0–43.0)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="31253" xml_f="31258" txt_i="11122" txt_f="11127">0.081</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="31313" xml_f="31340" txt_i="11128" txt_f="11155">C-reactive protein (nmol/L)</offsets><xref ref-type="table-fn" rid="t001fn002"><sup><offsets xml_i="31387" xml_f="31388" txt_i="11155" txt_f="11156">a</offsets></sup></xref><sup><offsets xml_i="31406" xml_f="31407" txt_i="11156" txt_f="11157">,</offsets></sup><xref ref-type="table-fn" rid="t001fn003"><sup><offsets xml_i="31460" xml_f="31461" txt_i="11157" txt_f="11158">b</offsets></sup></xref></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="31522" xml_f="31537" txt_i="11159" txt_f="11174">10.5 (1.9–37.9)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="31585" xml_f="31600" txt_i="11175" txt_f="11190">12.4 (1.0–58.6)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="31648" xml_f="31653" txt_i="11191" txt_f="11196">0.351</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="31708" xml_f="31723" txt_i="11197" txt_f="11212">Sodium (mmol/L)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="31771" xml_f="31782" txt_i="11213" txt_f="11224">140.6 ± 2.2</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="31830" xml_f="31841" txt_i="11225" txt_f="11236">140.5 ± 2.4</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="31889" xml_f="31894" txt_i="11237" txt_f="11242">0.705</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="31949" xml_f="31967" txt_i="11243" txt_f="11261">Potassium (mmol/L)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="32015" xml_f="32024" txt_i="11262" txt_f="11271">5.1 ± 0.6</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="32072" xml_f="32081" txt_i="11272" txt_f="11281">5.0 ± 0.6</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="32129" xml_f="32134" txt_i="11282" txt_f="11287">0.045</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="32189" xml_f="32206" txt_i="11288" txt_f="11305">Chloride (mmol/L)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="32254" xml_f="32265" txt_i="11306" txt_f="11317">108.7 ± 3.4</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="32313" xml_f="32324" txt_i="11318" txt_f="11329">107.5 ± 3.8</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="32372" xml_f="32377" txt_i="11330" txt_f="11335">0.001</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="32432" xml_f="32440" txt_i="11336" txt_f="11344">Total CO</offsets><sub><offsets xml_i="32445" xml_f="32446" txt_i="11344" txt_f="11345">2</offsets></sub><offsets xml_i="32452" xml_f="32461" txt_i="11345" txt_f="11354"> (mmol/L)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="32509" xml_f="32519" txt_i="11355" txt_f="11365">24.0 ± 2.9</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="32567" xml_f="32577" txt_i="11366" txt_f="11376">21.6 ± 3.3</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="32625" xml_f="32635" txt_i="11377" txt_f="11384">&lt; 0.001</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="32690" xml_f="32702" txt_i="11385" txt_f="11397">SAG (mmol/L)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="32750" xml_f="32759" txt_i="11398" txt_f="11407">7.9 ± 1.7</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="32807" xml_f="32817" txt_i="11408" txt_f="11418">11.5 ± 2.1</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="32865" xml_f="32875" txt_i="11419" txt_f="11426">&lt; 0.001</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="32930" xml_f="32944" txt_i="11427" txt_f="11441">A-SAG (mmol/L)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="32992" xml_f="33001" txt_i="11442" txt_f="11451">7.8 ± 1.4</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="33049" xml_f="33059" txt_i="11452" txt_f="11462">11.5 ± 1.9</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="33107" xml_f="33117" txt_i="11463" txt_f="11470">&lt; 0.001</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="33172" xml_f="33197" txt_i="11471" txt_f="11496">Log serum total IS (mg/L)</offsets><xref ref-type="table-fn" rid="t001fn003"><sup><offsets xml_i="33244" xml_f="33245" txt_i="11496" txt_f="11497">b</offsets></sup></xref></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="33306" xml_f="33315" txt_i="11498" txt_f="11507">1.4 ± 1.1</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="33363" xml_f="33372" txt_i="11508" txt_f="11517">1.4 ± 1.3</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="33420" xml_f="33425" txt_i="11518" txt_f="11523">0.970</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="33480" xml_f="33497" txt_i="11524" txt_f="11541">Serum B2MG (mg/L)</offsets><xref ref-type="table-fn" rid="t001fn003"><sup><offsets xml_i="33544" xml_f="33545" txt_i="11541" txt_f="11542">b</offsets></sup></xref></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="33606" xml_f="33615" txt_i="11543" txt_f="11552">6.5 ± 2.5</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="33663" xml_f="33672" txt_i="11553" txt_f="11562">6.9 ± 2.7</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="33720" xml_f="33725" txt_i="11563" txt_f="11568">0.102</offsets></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p><offsets xml_i="33805" xml_f="34232" txt_i="11569" txt_f="11996">Values were expressed as mean ± standard deviation for continuous variables and n/total (%) for categorical variables. Differences were evaluated by t-test or Mann-Whitney U test for continuous variables, and chi-square test for categorical variables. BP, blood pressure; eGFR, estimated glomerular filtration rate; SAG, serum anion gap; A-SAG, albumin-adjusted serum anion gap; IS, indoxyl sulfate; B2MG, beta-2 microglobulin.</offsets></p></fn><fn id="t001fn002"><p><sup><offsets xml_i="34268" xml_f="34269" txt_i="11997" txt_f="11998">a</offsets></sup><offsets xml_i="34275" xml_f="34451" txt_i="11998" txt_f="12174"> denotes variables with non-normal distribution. Values were expressed as median (interquartile range) and differences were evaluated by Mann-Whitney U test in these variables.</offsets></p></fn><fn id="t001fn003"><p><sup><offsets xml_i="34487" xml_f="34488" txt_i="12175" txt_f="12176">b</offsets></sup><offsets xml_i="34494" xml_f="34575" txt_i="12176" txt_f="12257"> denotes incomplete data. The missing rates of the variables were less than 6.1%.</offsets></p></fn></table-wrap-foot></table-wrap><p><offsets xml_i="34618" xml_f="34760" txt_i="12258" txt_f="12400">We performed univariate and multivariate Cox-proportional hazard regression analysis to identify factors associated with all-cause mortality (</offsets><xref ref-type="table" rid="pone.0156381.t002"><offsets xml_i="34807" xml_f="34814" txt_i="12400" txt_f="12407">Table 2</offsets></xref><offsets xml_i="34821" xml_f="35252" txt_i="12407" txt_f="12838">). The A-SAG ≥ 9.48 mmol/L was significantly associated with increased risk of all-cause mortality. In addition, older age, lower eGFR, higher serum beta-2 microglobulin (B2MG) and BUN were also significantly associated with increased risk of all-cause mortality. After adjusting for confounders, A-SAG ≥ 9.48 mmol/L was still associated with the increased risk of all-cause mortality, with hazard ratio 2.968 (95% CI 1.143–7.708, </offsets><italic><offsets xml_i="35260" xml_f="35261" txt_i="12838" txt_f="12839">P</offsets></italic><offsets xml_i="35270" xml_f="35280" txt_i="12839" txt_f="12849"> = 0.025).</offsets></p><table-wrap id="pone.0156381.t002" orientation="portrait" position="float"><object-id pub-id-type="doi"><offsets xml_i="35388" xml_f="35421" txt_i="12850" txt_f="12883">10.1371/journal.pone.0156381.t002</offsets></object-id><label><offsets xml_i="35440" xml_f="35447" txt_i="12883" txt_f="12890">Table 2</offsets></label><caption><title><offsets xml_i="35471" xml_f="35562" txt_i="12890" txt_f="12981">Factors associated with all-cause mortality in Cox-proportional hazard regression analysis.</offsets></title></caption><alternatives><graphic id="pone.0156381.t002g" xlink:href="pone.0156381.t002"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"></th><th align="center" colspan="2" rowspan="1"><offsets xml_i="36080" xml_f="36090" txt_i="12982" txt_f="12992">Univariate</offsets></th><th align="center" colspan="2" rowspan="1"><offsets xml_i="36138" xml_f="36150" txt_i="12992" txt_f="13004">Multivariate</offsets></th></tr><tr><th align="left" rowspan="1" colspan="1"></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="36253" xml_f="36264" txt_i="13004" txt_f="13015">HR (95% CI)</offsets></th><th align="center" rowspan="1" colspan="1"><italic><offsets xml_i="36320" xml_f="36321" txt_i="13015" txt_f="13016">P</offsets></italic></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="36378" xml_f="36389" txt_i="13016" txt_f="13027">HR (95% CI)</offsets></th><th align="center" rowspan="1" colspan="1"><italic><offsets xml_i="36445" xml_f="36446" txt_i="13027" txt_f="13028">P</offsets></italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="36525" xml_f="36550" txt_i="13028" txt_f="13053">Age (per 1 year increase)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="36598" xml_f="36617" txt_i="13054" txt_f="13073">1.099 (1.055–1.144)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="36665" xml_f="36675" txt_i="13074" txt_f="13081">&lt; 0.001</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="36723" xml_f="36742" txt_i="13082" txt_f="13101">1.086 (1.044–1.130)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="36790" xml_f="36800" txt_i="13102" txt_f="13109">&lt; 0.001</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="36855" xml_f="36876" txt_i="13110" txt_f="13131">Sex (male vs. female)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="36924" xml_f="36943" txt_i="13132" txt_f="13151">1.381 (0.612–3.118)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="36991" xml_f="36996" txt_i="13152" txt_f="13157">0.437</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="37044" xml_f="37063" txt_i="13158" txt_f="13177">2.251 (0.902–5.613)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="37111" xml_f="37116" txt_i="13178" txt_f="13183">0.082</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="37171" xml_f="37204" txt_i="13184" txt_f="13217">Diabetic nephropathy (yes vs. no)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="37252" xml_f="37271" txt_i="13218" txt_f="13237">1.713 (0.818–3.588)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="37319" xml_f="37324" txt_i="13238" txt_f="13243">0.154</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="37372" xml_f="37373" txt_i="13244" txt_f="13245">-</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="37421" xml_f="37422" txt_i="13246" txt_f="13247">-</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="37477" xml_f="37510" txt_i="13248" txt_f="13281">Systolic BP (per 1 mmHg increase)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="37558" xml_f="37577" txt_i="13282" txt_f="13301">1.013 (0.987–1.039)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="37625" xml_f="37630" txt_i="13302" txt_f="13307">0.331</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="37678" xml_f="37679" txt_i="13308" txt_f="13309">-</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="37727" xml_f="37728" txt_i="13310" txt_f="13311">-</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="37783" xml_f="37823" txt_i="13312" txt_f="13352">Randomization (intervention vs. control)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="37871" xml_f="37890" txt_i="13353" txt_f="13372">0.971 (0.469–2.012)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="37938" xml_f="37943" txt_i="13373" txt_f="13378">0.937</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="37991" xml_f="37992" txt_i="13379" txt_f="13380">-</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="38040" xml_f="38041" txt_i="13381" txt_f="13382">-</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="38096" xml_f="38120" txt_i="13383" txt_f="13407">eGFR (per 1 mL/min/1.73m</offsets><sup><offsets xml_i="38125" xml_f="38126" txt_i="13407" txt_f="13408">2</offsets></sup><offsets xml_i="38132" xml_f="38142" txt_i="13408" txt_f="13418"> increase)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="38190" xml_f="38209" txt_i="13419" txt_f="13438">0.899 (0.842–0.960)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="38257" xml_f="38262" txt_i="13439" txt_f="13444">0.002</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="38310" xml_f="38329" txt_i="13445" txt_f="13464">0.933 (0.832–1.046)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="38377" xml_f="38382" txt_i="13465" txt_f="13470">0.235</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="38437" xml_f="38464" txt_i="13471" txt_f="13498">SAG (per 1 mmol/L increase)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="38512" xml_f="38531" txt_i="13499" txt_f="13518">1.096 (0.959–1.253)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="38579" xml_f="38584" txt_i="13519" txt_f="13524">0.179</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="38632" xml_f="38633" txt_i="13525" txt_f="13526">-</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="38681" xml_f="38682" txt_i="13527" txt_f="13528">-</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="38737" xml_f="38767" txt_i="13529" txt_f="13556">A-SAG (≥ vs. &lt; 9.48 mmol/L)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="38815" xml_f="38834" txt_i="13557" txt_f="13576">2.917 (1.187–7.166)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="38882" xml_f="38887" txt_i="13577" txt_f="13582">0.020</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="38935" xml_f="38954" txt_i="13583" txt_f="13602">2.968 (1.143–7.708)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="39002" xml_f="39007" txt_i="13603" txt_f="13608">0.025</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="39062" xml_f="39105" txt_i="13609" txt_f="13652">Inorganic phosphorus (per 1mmol/L increase)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="39153" xml_f="39172" txt_i="13653" txt_f="13672">1.049 (0.227–4.840)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="39220" xml_f="39225" txt_i="13673" txt_f="13678">0.951</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="39273" xml_f="39292" txt_i="13679" txt_f="13698">0.722 (0.119–4.373)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="39340" xml_f="39345" txt_i="13699" txt_f="13704">0.723</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="39400" xml_f="39414" txt_i="13705" txt_f="13719">Serum Total CO</offsets><sub><offsets xml_i="39419" xml_f="39420" txt_i="13719" txt_f="13720">2</offsets></sub><offsets xml_i="39426" xml_f="39450" txt_i="13720" txt_f="13744"> (per 1 mmol/L increase)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="39498" xml_f="39517" txt_i="13745" txt_f="13764">0.937 (0.843–1.041)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="39565" xml_f="39570" txt_i="13765" txt_f="13770">0.227</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="39618" xml_f="39637" txt_i="13771" txt_f="13790">1.036 (0.919–1.167)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="39685" xml_f="39690" txt_i="13791" txt_f="13796">0.567</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="39745" xml_f="39776" txt_i="13797" txt_f="13828">Serum B2MG (per 1mg/L increase)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="39824" xml_f="39843" txt_i="13829" txt_f="13848">1.238 (1.107–1.383)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="39891" xml_f="39900" txt_i="13849" txt_f="13855">&lt;0.001</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="39948" xml_f="39967" txt_i="13856" txt_f="13875">1.157 (0.962–1.390)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="40015" xml_f="40020" txt_i="13876" txt_f="13881">0.121</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="40075" xml_f="40116" txt_i="13882" txt_f="13923">Blood urea nitrogen (per mmol/L increase)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="40164" xml_f="40183" txt_i="13924" txt_f="13943">1.077 (1.015–1.143)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="40231" xml_f="40236" txt_i="13944" txt_f="13949">0.015</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="40284" xml_f="40303" txt_i="13950" txt_f="13969">1.006 (0.916–1.105)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="40351" xml_f="40356" txt_i="13970" txt_f="13975">0.897</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="40411" xml_f="40449" txt_i="13976" txt_f="14014">Log serum total IS (per mg/L increase)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="40497" xml_f="40516" txt_i="14015" txt_f="14034">1.309 (0.928–1.845)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="40564" xml_f="40569" txt_i="14035" txt_f="14040">0.125</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="40617" xml_f="40618" txt_i="14041" txt_f="14042">-</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="40666" xml_f="40667" txt_i="14043" txt_f="14044">-</offsets></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p><offsets xml_i="40747" xml_f="40784" txt_i="14045" txt_f="14082">Known risk factors or variables with </offsets><italic><offsets xml_i="40792" xml_f="40793" txt_i="14082" txt_f="14083">P</offsets></italic><offsets xml_i="40802" xml_f="41030" txt_i="14083" txt_f="14308"> &lt; 0.05 were integrated in multivariate analysis. BP, blood pressure; eGFR, estimated glomerular filtration rate; SAG, serum anion gap; A-SAG, albumin-adjusted serum anion gap; B2MG, beta-2 microglobulin; IS, indoxyl sulfate.</offsets></p></fn></table-wrap-foot></table-wrap><p><offsets xml_i="41073" xml_f="41275" txt_i="14309" txt_f="14511">To determine the reason for the association between A-SAG and all-cause mortality, we performed linear regression analysis for A-SAG and uremic toxins. The serum total IS was not associated with A-SAG (</offsets><xref ref-type="fig" rid="pone.0156381.g004"><offsets xml_i="41320" xml_f="41326" txt_i="14511" txt_f="14517">Fig 4A</offsets></xref><offsets xml_i="41333" xml_f="41398" txt_i="14517" txt_f="14582">), with beta (95% CI) 0.118 (-0.088–0.325). However, serum B2MG (</offsets><xref ref-type="fig" rid="pone.0156381.g004"><offsets xml_i="41443" xml_f="41449" txt_i="14582" txt_f="14588">Fig 4B</offsets></xref><offsets xml_i="41456" xml_f="41467" txt_i="14588" txt_f="14599">) and BUN (</offsets><xref ref-type="fig" rid="pone.0156381.g004"><offsets xml_i="41512" xml_f="41518" txt_i="14599" txt_f="14605">Fig 4C</offsets></xref><offsets xml_i="41525" xml_f="41643" txt_i="14605" txt_f="14723">) were positively associated with A-SAG, with beta (95% CI) 0.137 (0.044–0.230) and 0.094 (0.049–0.140), respectively.</offsets></p><fig id="pone.0156381.g004" orientation="portrait" position="float"><object-id pub-id-type="doi"><offsets xml_i="41744" xml_f="41777" txt_i="14724" txt_f="14757">10.1371/journal.pone.0156381.g004</offsets></object-id><label><offsets xml_i="41796" xml_f="41801" txt_i="14757" txt_f="14762">Fig 4</offsets></label><caption><title><offsets xml_i="41825" xml_f="41905" txt_i="14762" txt_f="14842">Associations between albumin-adjusted serum anion gap (A-SAG) and uremic toxins.</offsets></title><p><offsets xml_i="41916" xml_f="42051" txt_i="14843" txt_f="14978">A, B, and C designated serum total indoxyl sulfate (IS), serum beta-2 microglobulin (B2MG) and blood urea nitrogen (BUN), respectively.</offsets></p></caption><graphic xlink:href="pone.0156381.g004"></graphic></fig></sec><sec sec-type="conclusions" id="sec012"><title><offsets xml_i="42174" xml_f="42184" txt_i="14980" txt_f="14990">Discussion</offsets></title><p><offsets xml_i="42195" xml_f="42431" txt_i="14991" txt_f="15227">We evaluated the usefulness of A-SAG as a potential biomarker for all-cause mortality in advanced CKD patients. SAG is easily calculated from serum or plasma electrolytes. Since SAG is significantly affected by the serum albumin level [</offsets><xref rid="pone.0156381.ref005" ref-type="bibr"><offsets xml_i="42479" xml_f="42480" txt_i="15227" txt_f="15228">5</offsets></xref><offsets xml_i="42487" xml_f="42538" txt_i="15228" txt_f="15279">], we used A-SAG to increase the predictive value [</offsets><xref rid="pone.0156381.ref016" ref-type="bibr"><offsets xml_i="42586" xml_f="42588" txt_i="15279" txt_f="15281">16</offsets></xref><offsets xml_i="42595" xml_f="42883" txt_i="15281" txt_f="15569">]. To our knowledge, this is the first study to explore the clinical usefulness of A-SAG in advanced CKD patients. In addition, our study suggested that A-SAG ≥ 9.48 mmol/L in patients with advanced CKD might be derived from retained middle-molecular or small water-soluble uremic toxins.</offsets></p><p><offsets xml_i="42890" xml_f="43052" txt_i="15570" txt_f="15732">In our discrimination analysis, the best threshold of A-SAG for all-cause mortality was 9.48 mmol/L, which has traditionally been considered in the normal range [</offsets><xref rid="pone.0156381.ref005" ref-type="bibr"><offsets xml_i="43100" xml_f="43101" txt_i="15732" txt_f="15733">5</offsets></xref><offsets xml_i="43108" xml_f="43324" txt_i="15733" txt_f="15946">]. Patients with A-SAG ≥ 9.48 mmol/L showed 2.968 times higher risk of all-cause mortality than those with A-SAG &lt; 9.48 mmol/L. Although high SAG is generally thought to be tightly linked with metabolic acidosis [</offsets><xref rid="pone.0156381.ref020" ref-type="bibr"><offsets xml_i="43372" xml_f="43374" txt_i="15946" txt_f="15948">20</offsets></xref><offsets xml_i="43381" xml_f="43627" txt_i="15948" txt_f="16194">], our data suggested that A-SAG ≥ 9.48 mmol/L might be predictive of all-cause mortality in advanced CKD patients independently of metabolic acidosis. Abramowitz et al. reported similar results after analyzing 11,957 adults in NHANES 1999–2004 [</offsets><xref rid="pone.0156381.ref012" ref-type="bibr"><offsets xml_i="43675" xml_f="43677" txt_i="16194" txt_f="16196">12</offsets></xref><offsets xml_i="43684" xml_f="43850" txt_i="16196" txt_f="16362">]. Compared to the first quartile of A-SAG, the fourth quartile was associated with increased risk of all-cause mortality, with hazard ratio 1.62 (95% CI, 1.19–2.21, </offsets><italic><offsets xml_i="43858" xml_f="43859" txt_i="16362" txt_f="16363">P</offsets></italic><offsets xml_i="43868" xml_f="44065" txt_i="16363" txt_f="16560"> trend = 0.007). However, the meaning of their results differs from that of our study, since the majority (over 90%) of the study participants had normal kidney function (eGFR above 60 mL/min/1.73m</offsets><sup><offsets xml_i="44070" xml_f="44071" txt_i="16560" txt_f="16561">2</offsets></sup><offsets xml_i="44077" xml_f="44193" txt_i="16561" txt_f="16677">). In contrast, our study participants were only made up of advanced CKD patients, who a have higher risk of death [</offsets><xref rid="pone.0156381.ref002" ref-type="bibr"><offsets xml_i="44241" xml_f="44242" txt_i="16677" txt_f="16678">2</offsets></xref><offsets xml_i="44249" xml_f="44251" txt_i="16678" txt_f="16680">, </offsets><xref rid="pone.0156381.ref003" ref-type="bibr"><offsets xml_i="44299" xml_f="44300" txt_i="16680" txt_f="16681">3</offsets></xref><offsets xml_i="44307" xml_f="44309" txt_i="16681" txt_f="16683">, </offsets><xref rid="pone.0156381.ref021" ref-type="bibr"><offsets xml_i="44357" xml_f="44359" txt_i="16683" txt_f="16685">21</offsets></xref><offsets xml_i="44366" xml_f="44475" txt_i="16685" txt_f="16794">] and need more care. Although Abramowitz et al. used A-SAG, the values were far lower than the usual range [</offsets><xref rid="pone.0156381.ref005" ref-type="bibr"><offsets xml_i="44523" xml_f="44524" txt_i="16794" txt_f="16795">5</offsets></xref><offsets xml_i="44531" xml_f="44533" txt_i="16795" txt_f="16797">, </offsets><xref rid="pone.0156381.ref012" ref-type="bibr"><offsets xml_i="44581" xml_f="44583" txt_i="16797" txt_f="16799">12</offsets></xref><offsets xml_i="44590" xml_f="44697" txt_i="16799" txt_f="16906">]. In contrast, we adopted an equation for albumin-adjustment with a range similar to the usual reference [</offsets><xref rid="pone.0156381.ref016" ref-type="bibr"><offsets xml_i="44745" xml_f="44747" txt_i="16906" txt_f="16908">16</offsets></xref><offsets xml_i="44754" xml_f="44876" txt_i="16908" txt_f="17030">], and hence more easily applicable. Togawa et al. also analyzed 42 patients with advance CKD (eGFR 7.1–52.0 mL/min/1.73vm</offsets><sup><offsets xml_i="44881" xml_f="44882" txt_i="17030" txt_f="17031">2</offsets></sup><offsets xml_i="44888" xml_f="44945" txt_i="17031" txt_f="17088">) for the association between A-SAG and CKD progression [</offsets><xref rid="pone.0156381.ref013" ref-type="bibr"><offsets xml_i="44993" xml_f="44995" txt_i="17088" txt_f="17090">13</offsets></xref><offsets xml_i="45002" xml_f="45136" txt_i="17090" txt_f="17224">]. Although they suggested that A-SAG was significantly associated with delta eGFR/6 months in multiple linear regression (beta 0.45, </offsets><italic><offsets xml_i="45144" xml_f="45145" txt_i="17224" txt_f="17225">P</offsets></italic><offsets xml_i="45154" xml_f="45220" txt_i="17225" txt_f="17288"> &lt; 0.01), they did not evaluate the association with mortality.</offsets></p><p><offsets xml_i="45227" xml_f="45460" txt_i="17289" txt_f="17522">The reason why A-SAG ≥ 9.48 mmol/L is predictive of mortality in advanced CKD patients remains unclear. Although several studies have suggested that elevated SAG is associated with increased risk of mortality in various populations [</offsets><xref rid="pone.0156381.ref009" ref-type="bibr"><offsets xml_i="45508" xml_f="45509" txt_i="17522" txt_f="17523">9</offsets></xref><offsets xml_i="45516" xml_f="45517" txt_i="17523" txt_f="17524">–</offsets><xref rid="pone.0156381.ref012" ref-type="bibr"><offsets xml_i="45565" xml_f="45567" txt_i="17524" txt_f="17526">12</offsets></xref><offsets xml_i="45574" xml_f="46051" txt_i="17526" txt_f="18003">], none of the previous studies provided relevant evidence. The lower eGFR in A-SAG ≥ 9.48 mmol/L group can explain some of the excess mortality. But multivariate analysis revealed that the impact of A-SAG was valid even after controlling the effect of eGFR. According to our study results, we speculate that uremia itself might be the reason why elevated AG is associated with increased risk of mortality in advanced CKD patients. Uremia is an important cause of elevated AG [</offsets><xref rid="pone.0156381.ref020" ref-type="bibr"><offsets xml_i="46099" xml_f="46101" txt_i="18003" txt_f="18005">20</offsets></xref><offsets xml_i="46108" xml_f="46332" txt_i="18005" txt_f="18229">]. In retention of uremic toxins, decreased renal tubular secretion also plays an important role in addition to decreased glomerular filtration since some toxins, such as middle molecules, are too large to be filtered well [</offsets><xref rid="pone.0156381.ref022" ref-type="bibr"><offsets xml_i="46380" xml_f="46382" txt_i="18229" txt_f="18231">22</offsets></xref><offsets xml_i="46389" xml_f="46504" txt_i="18231" txt_f="18346">]. There is increasing evidences that a high level of uremic toxin is associated with increased risk of mortality [</offsets><xref rid="pone.0156381.ref023" ref-type="bibr"><offsets xml_i="46552" xml_f="46554" txt_i="18346" txt_f="18348">23</offsets></xref><offsets xml_i="46561" xml_f="46562" txt_i="18348" txt_f="18349">–</offsets><xref rid="pone.0156381.ref026" ref-type="bibr"><offsets xml_i="46610" xml_f="46612" txt_i="18349" txt_f="18351">26</offsets></xref><offsets xml_i="46619" xml_f="46803" txt_i="18351" txt_f="18535">]. In our study, we analyzed serum levels of total IS, B2MG, and BUN, as representatives of highly protein-bound, middle-molecular and small-water soluble uremic toxins, respectively [</offsets><xref rid="pone.0156381.ref027" ref-type="bibr"><offsets xml_i="46851" xml_f="46853" txt_i="18535" txt_f="18537">27</offsets></xref><offsets xml_i="46860" xml_f="46862" txt_i="18537" txt_f="18539">, </offsets><xref rid="pone.0156381.ref028" ref-type="bibr"><offsets xml_i="46910" xml_f="46912" txt_i="18539" txt_f="18541">28</offsets></xref><offsets xml_i="46919" xml_f="47000" txt_i="18541" txt_f="18622">]. Since serum B2MG has a negative charge at physiological pH, it acts as anion [</offsets><xref rid="pone.0156381.ref029" ref-type="bibr"><offsets xml_i="47048" xml_f="47050" txt_i="18622" txt_f="18624">29</offsets></xref><offsets xml_i="47057" xml_f="47396" txt_i="18624" txt_f="18963">]. We assumed this was the reason why the serum level of B2MG was positively associated with the level of A-SAG. BUN was also positively related to the level of A-SAG. We also found that the serum levels of B2MG and BUN were associated with increased risk of all-cause mortality, which was consistent with the results of previous studies [</offsets><xref rid="pone.0156381.ref023" ref-type="bibr"><offsets xml_i="47444" xml_f="47446" txt_i="18963" txt_f="18965">23</offsets></xref><offsets xml_i="47453" xml_f="47454" txt_i="18965" txt_f="18966">–</offsets><xref rid="pone.0156381.ref026" ref-type="bibr"><offsets xml_i="47502" xml_f="47504" txt_i="18966" txt_f="18968">26</offsets></xref><offsets xml_i="47511" xml_f="47691" txt_i="18968" txt_f="19148">]. However, serum level of total IS was not associated with the level of A-SAG and all-cause mortality in the study. Serum IS has a high affinity to serum protein, mostly albumin [</offsets><xref rid="pone.0156381.ref023" ref-type="bibr"><offsets xml_i="47739" xml_f="47741" txt_i="19148" txt_f="19150">23</offsets></xref><offsets xml_i="47748" xml_f="47952" txt_i="19150" txt_f="19354">]. Therefore serum level of total IS cannot reflect the serum level of free IS well. In fact, most of the literature showing a relationship between serum IS and mortality used the serum level of free IS [</offsets><xref rid="pone.0156381.ref024" ref-type="bibr"><offsets xml_i="48000" xml_f="48002" txt_i="19354" txt_f="19356">24</offsets></xref><offsets xml_i="48009" xml_f="48365" txt_i="19356" txt_f="19712">]. We believed this was the reason why the serum level of total IS was not associated with the level of A-SAG and all-cause mortality. Based on our result, we infer that the increased risk of A-SAG ≥ 9.48 mmol/L for all-cause mortality might be derived from the positive relationship between A-SAG and middle-molecular or small water-soluble uremic toxins.</offsets></p><p><offsets xml_i="48372" xml_f="48808" txt_i="19713" txt_f="20149">Although the contribution of uremic toxins in A-SAG might be an important reason for the increased risk of all-cause mortality, we also speculate that there may be different underlying mechanisms, since the explanatory power of uremic toxins for A-SAG was not high. We believe that A-SAG could a surrogate marker for a poor lifestyle. Gannon et al. explored dietary intake with respect to acid-base balance in an elderly UK population [</offsets><xref rid="pone.0156381.ref030" ref-type="bibr"><offsets xml_i="48856" xml_f="48858" txt_i="20149" txt_f="20151">30</offsets></xref><offsets xml_i="48865" xml_f="49090" txt_i="20151" txt_f="20376">]. They calculated net endogenous acid production, which is closely associated with dietary acids and organic anions. In their analysis, higher dietary acidity was significantly associated with higher consumption of protein (</offsets><italic><offsets xml_i="49098" xml_f="49099" txt_i="20376" txt_f="20377">P</offsets></italic><offsets xml_i="49108" xml_f="49180" txt_i="20377" txt_f="20446"> &lt; 0.02). Since most bases of dietary acids are weak organic anions [</offsets><xref rid="pone.0156381.ref030" ref-type="bibr"><offsets xml_i="49228" xml_f="49230" txt_i="20446" txt_f="20448">30</offsets></xref><offsets xml_i="49237" xml_f="49339" txt_i="20448" txt_f="20550">], elevated SAG would reflect high dietary acid and protein intake, which is harmful to CKD patients [</offsets><xref rid="pone.0156381.ref031" ref-type="bibr"><offsets xml_i="49387" xml_f="49389" txt_i="20550" txt_f="20552">31</offsets></xref><offsets xml_i="49396" xml_f="49637" txt_i="20552" txt_f="20793">]. Elevated SAG is also related to poor cardiorespiratory fitness. Abramowitz et al. analyzed the data of NHANES 1999–2004 for the association between elevated SAG and cardiorespiratory fitness, as determined by submaximal exercise testing [</offsets><xref rid="pone.0156381.ref032" ref-type="bibr"><offsets xml_i="49685" xml_f="49687" txt_i="20793" txt_f="20795">32</offsets></xref><offsets xml_i="49694" xml_f="49990" txt_i="20795" txt_f="21091">]. After adjustment, a 1-SD increase of SAG was associated with increased odds for poor fitness (odds ratio 1.30, 95% CI 1.15–1.48). We surmise that the poor lifestyle reflected by elevated SAG might be a potential reason why elevated SAG is associated with increased risk of all-cause mortality.</offsets></p><p><offsets xml_i="49997" xml_f="50158" txt_i="21092" txt_f="21250">Although the serum level of inorganic phosphrous was equal in both &lt; and ≥ 9.48 mmol/L of A-SAG groups in the current study, hyperphosphatemia can raise SAG [</offsets><xref rid="pone.0156381.ref005" ref-type="bibr"><offsets xml_i="50206" xml_f="50207" txt_i="21250" txt_f="21251">5</offsets></xref><offsets xml_i="50214" xml_f="50306" txt_i="21251" txt_f="21343">]. Since hyperphosphatemia and secondary hyperparathyroidism are associated with mortality [</offsets><xref rid="pone.0156381.ref033" ref-type="bibr"><offsets xml_i="50354" xml_f="50356" txt_i="21343" txt_f="21345">33</offsets></xref><offsets xml_i="50363" xml_f="50364" txt_i="21345" txt_f="21346">–</offsets><xref rid="pone.0156381.ref035" ref-type="bibr"><offsets xml_i="50412" xml_f="50414" txt_i="21346" txt_f="21348">35</offsets></xref><offsets xml_i="50421" xml_f="50604" txt_i="21348" txt_f="21531">], we assumed that hyperphosphatemia and related secondary hyperparathyroidism in patients with elevated SAG are also a good explanation for the association between SAG and mortality.</offsets></p><p><offsets xml_i="50611" xml_f="50735" txt_i="21532" txt_f="21656">The current study had several limitations. First, the current study was retrospective, and important values such as total CO</offsets><sub><offsets xml_i="50740" xml_f="50741" txt_i="21656" txt_f="21657">2</offsets></sub><offsets xml_i="50747" xml_f="51533" txt_i="21657" txt_f="22443"> were not available at randomization and subsequent visits since the original study did not aim to evaluate the impact of SAG on clinical outcomes. In the study, the outcome relied on retrospective medical chart review, which might underreport the true mortality. In addition, we did not have detailed data on causes of death, except for cardiovascular mortality, which was too low (2.5%) to perform reliable analysis. Second, the association between uremic toxins and A-SAG was analyzed cross-sectionally, and a causal relationship could not be confirmed. Despite this weakness, our results are useful, because they show the relationship between uremic toxins and A-SAG for the first time. Finally, all participants of the original study were Asians, which limits the generalizability.</offsets></p><p><offsets xml_i="51540" xml_f="52176" txt_i="22444" txt_f="23080">In conclusion, the level of A-SAG is an independent risk factor for all-cause mortality in advanced CKD patients. Currently, nephrologists who care advanced CKD patients have no easily accessible biomarkers beyond serum creatinine. In this regard, A-SAG can be a cheap and effective guide. Based on our study results, clinicians can warn a patient with A-SAG ≥ 9.48 mmol/L for the poor prognosis, and recommend stricter adherence to the medication and good life style with more frequent clinic visits for timely interventions. The effective way to lower A-SAG and the efficacy of A-SAG lowering intervention needs further investigation.</offsets></p></sec><sec sec-type="supplementary-material" id="sec013"><title><offsets xml_i="52244" xml_f="52266" txt_i="23082" txt_f="23104">Supporting Information</offsets></title><supplementary-material content-type="local-data" id="pone.0156381.s001"><label><offsets xml_i="52354" xml_f="52362" txt_i="23105" txt_f="23113">S1 Table</offsets></label><caption><title><offsets xml_i="52386" xml_f="52476" txt_i="23113" txt_f="23203">Multivariate Cox-proportional hazard regression of A-SAG quintile and all-cause mortality.</offsets></title><p><offsets xml_i="52487" xml_f="52493" txt_i="23204" txt_f="23210">(DOCX)</offsets></p></caption><media xlink:href="pone.0156381.s001.docx"><caption><p><offsets xml_i="52562" xml_f="52598" txt_i="23211" txt_f="23247">Click here for additional data file.</offsets></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0156381.s002"><label><offsets xml_i="52725" xml_f="52733" txt_i="23248" txt_f="23256">S2 Table</offsets></label><caption><title><offsets xml_i="52757" xml_f="52861" txt_i="23256" txt_f="23360">Multivariate Cox-proportional hazard regression of several A-SAG cut-points for the all-cause mortality.</offsets></title><p><offsets xml_i="52872" xml_f="52878" txt_i="23361" txt_f="23367">(DOCX)</offsets></p></caption><media xlink:href="pone.0156381.s002.docx"><caption><p><offsets xml_i="52947" xml_f="52983" txt_i="23368" txt_f="23404">Click here for additional data file.</offsets></p></caption></media></supplementary-material></sec></body><back><ack><p>We thank Seon Ha Baek and Hyun-jin Cho for their great help.</p></ack><ref-list><title>References</title><ref id="pone.0156381.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>SW</given-names></name>, <name><surname>Kim</surname><given-names>YC</given-names></name>, <name><surname>Oh</surname><given-names>SW</given-names></name>, <name><surname>Koo</surname><given-names>HS</given-names></name>, <name><surname>Na</surname><given-names>KY</given-names></name>, <name><surname>Chae</surname><given-names>DW</given-names></name>, <etal>et al</etal>
<article-title>Trends in the prevalence of chronic kidney disease, other chronic diseases and health-related behaviors in an adult Korean population: data from the Korean National Health and Nutrition Examination Survey (KNHANES)</article-title>. <source>Nephrol Dial Transplant</source>.<year>2011</year>;<volume>26</volume>(<issue>12</issue>):<fpage>3975</fpage>–<lpage>80</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/ndt/gfr154">10.1093/ndt/gfr154</ext-link></comment> .<pub-id pub-id-type="pmid">21454352</pub-id></mixed-citation></ref><ref id="pone.0156381.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Go</surname><given-names>AS</given-names></name>, <name><surname>Chertow</surname><given-names>GM</given-names></name>, <name><surname>Fan</surname><given-names>D</given-names></name>, <name><surname>McCulloch</surname><given-names>CE</given-names></name>, <name><surname>Hsu</surname><given-names>CY</given-names></name>. <article-title>Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization</article-title>. <source>N Engl J Med</source>. <year>2004</year>;<volume>351</volume>(<issue>13</issue>):<fpage>1296</fpage>–<lpage>305</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMoa041031">10.1056/NEJMoa041031</ext-link></comment> .<pub-id pub-id-type="pmid">15385656</pub-id></mixed-citation></ref><ref id="pone.0156381.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Weiner</surname><given-names>DE</given-names></name>, <name><surname>Tighiouart</surname><given-names>H</given-names></name>, <name><surname>Amin</surname><given-names>MG</given-names></name>, <name><surname>Stark</surname><given-names>PC</given-names></name>, <name><surname>MacLeod</surname><given-names>B</given-names></name>, <name><surname>Griffith</surname><given-names>JL</given-names></name>, <etal>et al</etal>
<article-title>Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies</article-title>. <source>J Am Soc Nephrol</source>. <year>2004</year>;<volume>15</volume>(<issue>5</issue>):<fpage>1307</fpage>–<lpage>15</lpage>. .<pub-id pub-id-type="pmid">15100371</pub-id></mixed-citation></ref><ref id="pone.0156381.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Sun</surname><given-names>W</given-names></name>, <name><surname>Liu</surname><given-names>D</given-names></name>, <name><surname>Gong</surname><given-names>P</given-names></name>, <name><surname>Shi</surname><given-names>X</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Predicting cardiovascular mortality in chronic kidney disease (CKD) patients</article-title>. <source>Ann Transplant</source>. <year>2014</year>;<volume>19</volume>:<fpage>513</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.12659/AOT.891207">10.12659/AOT.891207</ext-link></comment> .<pub-id pub-id-type="pmid">25315215</pub-id></mixed-citation></ref><ref id="pone.0156381.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Kraut</surname><given-names>JA</given-names></name>, <name><surname>Madias</surname><given-names>NE</given-names></name>. <article-title>Serum anion gap: its uses and limitations in clinical medicine</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>2007</year>;<volume>2</volume>(<issue>1</issue>):<fpage>162</fpage>–<lpage>74</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2215/CJN.03020906">10.2215/CJN.03020906</ext-link></comment> .<pub-id pub-id-type="pmid">17699401</pub-id></mixed-citation></ref><ref id="pone.0156381.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Taylor</surname><given-names>EN</given-names></name>, <name><surname>Forman</surname><given-names>JP</given-names></name>, <name><surname>Farwell</surname><given-names>WR</given-names></name>. <article-title>Serum anion gap and blood pressure in the national health and nutrition examination survey</article-title>. <source>Hypertension</source>. <year>2007</year>;<volume>50</volume>(<issue>2</issue>):<fpage>320</fpage>–<lpage>4</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/HYPERTENSIONAHA.107.092643">10.1161/HYPERTENSIONAHA.107.092643</ext-link></comment> .<pub-id pub-id-type="pmid">17562979</pub-id></mixed-citation></ref><ref id="pone.0156381.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Farwell</surname><given-names>WR</given-names></name>, <name><surname>Taylor</surname><given-names>EN</given-names></name>. <article-title>Serum bicarbonate, anion gap and insulin resistance in the National Health and Nutrition Examination Survey</article-title>. <source>Diabet Med</source>. <year>2008</year>;<volume>25</volume>(<issue>7</issue>):<fpage>798</fpage>–<lpage>804</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1464-5491.2008.02471.x">10.1111/j.1464-5491.2008.02471.x</ext-link></comment> .<pub-id pub-id-type="pmid">18644066</pub-id></mixed-citation></ref><ref id="pone.0156381.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Farwell</surname><given-names>WR</given-names></name>, <name><surname>Taylor</surname><given-names>EN</given-names></name>. <article-title>Serum anion gap, bicarbonate and biomarkers of inflammation in healthy individuals in a national survey</article-title>. <source>CMAJ</source>. <year>2010</year>;<volume>182</volume>(<issue>2</issue>):<fpage>137</fpage>–<lpage>41</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1503/cmaj.090329">10.1503/cmaj.090329</ext-link></comment> ; PubMed Central PMCID: PMC2817320.<pub-id pub-id-type="pmid">20008503</pub-id></mixed-citation></ref><ref id="pone.0156381.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Sahu</surname><given-names>A</given-names></name>, <name><surname>Cooper</surname><given-names>HA</given-names></name>, <name><surname>Panza</surname><given-names>JA</given-names></name>. <article-title>The initial anion gap is a predictor of mortality in acute myocardial infarction</article-title>. <source>Coron Artery Dis</source>. <year>2006</year>;<volume>17</volume>(<issue>5</issue>):<fpage>409</fpage>–<lpage>12</lpage>. .<pub-id pub-id-type="pmid">16845247</pub-id></mixed-citation></ref><ref id="pone.0156381.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Lipnick</surname><given-names>MS</given-names></name>, <name><surname>Braun</surname><given-names>AB</given-names></name>, <name><surname>Cheung</surname><given-names>JT</given-names></name>, <name><surname>Gibbons</surname><given-names>FK</given-names></name>, <name><surname>Christopher</surname><given-names>KB</given-names></name>. <article-title>The difference between critical care initiation anion gap and prehospital admission anion gap is predictive of mortality in critical illness</article-title>. <source>Crit Care Med</source>. <year>2013</year>;<volume>41</volume>(<issue>1</issue>):<fpage>49</fpage>–<lpage>59</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/CCM.0b013e31826764cd">10.1097/CCM.0b013e31826764cd</ext-link></comment> .<pub-id pub-id-type="pmid">23190721</pub-id></mixed-citation></ref><ref id="pone.0156381.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Ahn</surname><given-names>SY</given-names></name>, <name><surname>Ryu</surname><given-names>J</given-names></name>, <name><surname>Baek</surname><given-names>SH</given-names></name>, <name><surname>Han</surname><given-names>JW</given-names></name>, <name><surname>Lee</surname><given-names>JH</given-names></name>, <name><surname>Ahn</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Serum anion gap is predictive of mortality in an elderly population</article-title>. <source>Exp Gerontol</source>. <year>2014</year>;<volume>50</volume>:<fpage>122</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.exger.2013.12.002">10.1016/j.exger.2013.12.002</ext-link></comment> .<pub-id pub-id-type="pmid">24333141</pub-id></mixed-citation></ref><ref id="pone.0156381.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Abramowitz</surname><given-names>MK</given-names></name>, <name><surname>Hostetter</surname><given-names>TH</given-names></name>, <name><surname>Melamed</surname><given-names>ML</given-names></name>. <article-title>The serum anion gap is altered in early kidney disease and associates with mortality</article-title>. <source>Kidney Int</source>. <year>2012</year>;<volume>82</volume>(<issue>6</issue>):<fpage>701</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ki.2012.196">10.1038/ki.2012.196</ext-link></comment> ; PubMed Central PMCID: PMC3434284.<pub-id pub-id-type="pmid">22622500</pub-id></mixed-citation></ref><ref id="pone.0156381.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Togawa</surname><given-names>A</given-names></name>, <name><surname>Uyama</surname><given-names>S</given-names></name>, <name><surname>Takanohashi</surname><given-names>S</given-names></name>, <name><surname>Shimasaki</surname><given-names>M</given-names></name>, <name><surname>Miyaji</surname><given-names>T</given-names></name>, <name><surname>Endo</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Adjusted Anion Gap Is Associated with Glomerular Filtration Rate Decline in Chronic Kidney Disease</article-title>. <source>Nephron extra</source>. <year>2013</year>;<volume>3</volume>(<issue>1</issue>):<fpage>113</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1159/000356461">10.1159/000356461</ext-link></comment> ; PubMed Central PMCID: PMC3861847.<pub-id pub-id-type="pmid">24348507</pub-id></mixed-citation></ref><ref id="pone.0156381.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Cha</surname><given-names>RH</given-names></name>, <name><surname>Kang</surname><given-names>SW</given-names></name>, <name><surname>Park</surname><given-names>CW</given-names></name>, <name><surname>Cha</surname><given-names>DR</given-names></name>, <name><surname>Na</surname><given-names>KY</given-names></name>, <name><surname>Kim</surname><given-names>SG</given-names></name>, <etal>et al</etal>
<article-title>A Randomized, Controlled Trial of Oral Intestinal Sorbent AST-120 on Renal Function Deterioration in Patients with Advanced Renal Dysfunction</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>2016</year>;<volume>11</volume>(<issue>4</issue>):<fpage>559</fpage>–<lpage>67</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2215/CJN.12011214">10.2215/CJN.12011214</ext-link></comment> .<pub-id pub-id-type="pmid">26912554</pub-id></mixed-citation></ref><ref id="pone.0156381.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Levey</surname><given-names>AS</given-names></name>, <name><surname>Stevens</surname><given-names>LA</given-names></name>, <name><surname>Schmid</surname><given-names>CH</given-names></name>, <name><surname>Zhang</surname><given-names>YL</given-names></name>, <name><surname>Castro</surname><given-names>AF</given-names><suffix>3rd</suffix></name>, <name><surname>Feldman</surname><given-names>HI</given-names></name>, <etal>et al</etal>
<article-title>A new equation to estimate glomerular filtration rate</article-title>. <source>Ann Intern Med</source>. <year>2009</year>;<volume>150</volume>(<issue>9</issue>):<fpage>604</fpage>–<lpage>12</lpage>. Epub 2009/05/06. 150/9/604 [pii]. ; PubMed Central PMCID: PMC2763564.<pub-id pub-id-type="pmid">19414839</pub-id></mixed-citation></ref><ref id="pone.0156381.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Figge</surname><given-names>J</given-names></name>, <name><surname>Jabor</surname><given-names>A</given-names></name>, <name><surname>Kazda</surname><given-names>A</given-names></name>, <name><surname>Fencl</surname><given-names>V</given-names></name>. <article-title>Anion gap and hypoalbuminemia</article-title>. <source>Crit Care Med</source>. <year>1998</year>;<volume>26</volume>(<issue>11</issue>):<fpage>1807</fpage>–<lpage>10</lpage>. .<pub-id pub-id-type="pmid">9824071</pub-id></mixed-citation></ref><ref id="pone.0156381.ref017"><label>17</label><mixed-citation publication-type="other">R Core Team (2014) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available: <ext-link ext-link-type="uri" xlink:href="https://www.R-project.org/">https://www.R-project.org/</ext-link>.</mixed-citation></ref><ref id="pone.0156381.ref018"><label>18</label><mixed-citation publication-type="other">Frank E Harrell Jr (2015) rms: Regression Modeling Strategies. R package version 4.3–0. Available: <ext-link ext-link-type="uri" xlink:href="http://CRAN.R-project.org/package=rms">http://CRAN.R-project.org/package=rms</ext-link>.</mixed-citation></ref><ref id="pone.0156381.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Robin</surname><given-names>X</given-names></name>, <name><surname>Turck</surname><given-names>N</given-names></name>, <name><surname>Hainard</surname><given-names>A</given-names></name>, <name><surname>Tiberti</surname><given-names>N</given-names></name>, <name><surname>Lisacek</surname><given-names>F</given-names></name>, <name><surname>Sanchez</surname><given-names>J-C</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>pROC: an open-source package for R and S+ to analyze and compare ROC curves</article-title>. <source>BMC Bioinformatics</source>, <volume>12</volume>, p.77. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2105-12-77">10.1186/1471-2105-12-77</ext-link></comment> &lt;<ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2105/12/77/">http://www.biomedcentral.com/1471-2105/12/77/</ext-link>&gt;.</mixed-citation></ref><ref id="pone.0156381.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Mehta</surname><given-names>AN</given-names></name>, <name><surname>Emmett</surname><given-names>JB</given-names></name>, <name><surname>Emmett</surname><given-names>M</given-names></name>. <article-title>GOLD MARK: an anion gap mnemonic for the 21st century</article-title>. <source>Lancet</source>. <year>2008</year>;<volume>372</volume>(<issue>9642</issue>):<fpage>892</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0140-6736(08)61398-7">10.1016/S0140-6736(08)61398-7</ext-link></comment> .<pub-id pub-id-type="pmid">18790311</pub-id></mixed-citation></ref><ref id="pone.0156381.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Kiuchi</surname><given-names>MG</given-names></name>, <name><surname>Mion</surname><given-names>D</given-names><suffix>Jr</suffix></name>. <article-title>Chronic kidney disease and risk factors responsible for sudden cardiac death: a whiff of hope?</article-title>
<source>Kidney Res Clin Pract</source>. <year>2016</year>;<volume>35</volume>(<issue>1</issue>):<fpage>3</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.krcp.2015.11.003">10.1016/j.krcp.2015.11.003</ext-link></comment> ; PubMed Central PMCID: PMC4811986.<pub-id pub-id-type="pmid">27069851</pub-id></mixed-citation></ref><ref id="pone.0156381.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Masereeuw</surname><given-names>R</given-names></name>, <name><surname>Mutsaers</surname><given-names>HA</given-names></name>, <name><surname>Toyohara</surname><given-names>T</given-names></name>, <name><surname>Abe</surname><given-names>T</given-names></name>, <name><surname>Jhawar</surname><given-names>S</given-names></name>, <name><surname>Sweet</surname><given-names>DH</given-names></name>, <etal>et al</etal> T<article-title>he kidney and uremic toxin removal: glomerulus or tubule?</article-title>
<source>Semin Nephrol</source>. <year>2014</year>;<volume>34</volume>(<issue>2</issue>):<fpage>191</fpage>–<lpage>208</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.semnephrol.2014.02.010">10.1016/j.semnephrol.2014.02.010</ext-link></comment> .<pub-id pub-id-type="pmid">24780473</pub-id></mixed-citation></ref><ref id="pone.0156381.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Vanholder</surname><given-names>R</given-names></name>, <name><surname>Schepers</surname><given-names>E</given-names></name>, <name><surname>Pletinck</surname><given-names>A</given-names></name>, <name><surname>Nagler</surname><given-names>EV</given-names></name>, <name><surname>Glorieux</surname><given-names>G</given-names></name>. <article-title>The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review</article-title>. <source>J Am Soc Nephrol</source>. <year>2014</year>;<volume>25</volume>(<issue>9</issue>):<fpage>1897</fpage>–<lpage>907</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1681/ASN.2013101062">10.1681/ASN.2013101062</ext-link></comment> ; PubMed Central PMCID: PMC4147984.<pub-id pub-id-type="pmid">24812165</pub-id></mixed-citation></ref><ref id="pone.0156381.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>CJ</given-names></name>, <name><surname>Wu</surname><given-names>V</given-names></name>, <name><surname>Wu</surname><given-names>PC</given-names></name>, <name><surname>Wu</surname><given-names>CJ</given-names></name>. <article-title>Meta-Analysis of the Associations of p-Cresyl Sulfate (PCS) and Indoxyl Sulfate (IS) with Cardiovascular Events and All-Cause Mortality in Patients with Chronic Renal Failure</article-title>. <source>PloS one</source>. <year>2015</year>;<volume>10</volume>(<issue>7</issue>):<fpage>e0132589</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0132589">10.1371/journal.pone.0132589</ext-link></comment> ; PubMed Central PMCID: PMC4501756.<pub-id pub-id-type="pmid">26173073</pub-id></mixed-citation></ref><ref id="pone.0156381.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Shinkai</surname><given-names>S</given-names></name>, <name><surname>Chaves</surname><given-names>PH</given-names></name>, <name><surname>Fujiwara</surname><given-names>Y</given-names></name>, <name><surname>Watanabe</surname><given-names>S</given-names></name>, <name><surname>Shibata</surname><given-names>H</given-names></name>, <name><surname>Yoshida</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Beta2-microglobulin for risk stratification of total mortality in the elderly population: comparison with cystatin C and C-reactive protein</article-title>. <source>Arch Intern Med</source>. <year>2008</year>;<volume>168</volume>(<issue>2</issue>):<fpage>200</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/archinternmed.2007.64">10.1001/archinternmed.2007.64</ext-link></comment> .<pub-id pub-id-type="pmid">18227369</pub-id></mixed-citation></ref><ref id="pone.0156381.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Canaud</surname><given-names>B</given-names></name>, <name><surname>Morena</surname><given-names>M</given-names></name>, <name><surname>Cristol</surname><given-names>JP</given-names></name>, <name><surname>Krieter</surname><given-names>D</given-names></name>. <article-title>Beta2-microglobulin, a uremic toxin with a double meaning</article-title>. <source>Kidney int</source>. <year>2006</year>;<volume>69</volume>(<issue>8</issue>):<fpage>1297</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/sj.ki.5000389">10.1038/sj.ki.5000389</ext-link></comment> .<pub-id pub-id-type="pmid">16612412</pub-id></mixed-citation></ref><ref id="pone.0156381.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Vanholder</surname><given-names>R</given-names></name>, <name><surname>De Smet</surname><given-names>R</given-names></name>, <name><surname>Glorieux</surname><given-names>G</given-names></name>, <name><surname>Argiles</surname><given-names>A</given-names></name>, <name><surname>Baurmeister</surname><given-names>U</given-names></name>, <name><surname>Brunet</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Review on uremic toxins: classification, concentration, and interindividual variability</article-title>. <source>Kidney int</source>. <year>2003</year>;<volume>63</volume>(<issue>5</issue>):<fpage>1934</fpage>–<lpage>43</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1046/j.1523-1755.2003.00924.x">10.1046/j.1523-1755.2003.00924.x</ext-link></comment> .<pub-id pub-id-type="pmid">12675874</pub-id></mixed-citation></ref><ref id="pone.0156381.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Duranton</surname><given-names>F</given-names></name>, <name><surname>Cohen</surname><given-names>G</given-names></name>, <name><surname>De Smet</surname><given-names>R</given-names></name>, <name><surname>Rodriguez</surname><given-names>M</given-names></name>, <name><surname>Jankowski</surname><given-names>J</given-names></name>, <name><surname>Vanholder</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Normal and pathologic concentrations of uremic toxins</article-title>. <source>J Am Soc Nephrol</source>. <year>2012</year>;<volume>23</volume>(<issue>7</issue>):<fpage>1258</fpage>–<lpage>70</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1681/ASN.2011121175">10.1681/ASN.2011121175</ext-link></comment> ; PubMed Central PMCID: PMC3380651.<pub-id pub-id-type="pmid">22626821</pub-id></mixed-citation></ref><ref id="pone.0156381.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Lindstrom</surname><given-names>V</given-names></name>, <name><surname>Grubb</surname><given-names>A</given-names></name>, <name><surname>Alquist Hegbrant</surname><given-names>M</given-names></name>, <name><surname>Christensson</surname><given-names>A</given-names></name>. <article-title>Different elimination patterns of beta-trace protein, beta2-microglobulin and cystatin C in haemodialysis, haemodiafiltration and haemofiltration</article-title>. <source>Scand J Clin Lab Invest</source>. <year>2008</year>;<volume>68</volume>(<issue>8</issue>):<fpage>685</fpage>–<lpage>91</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1080/00365510802047693">10.1080/00365510802047693</ext-link></comment> .<pub-id pub-id-type="pmid">18609120</pub-id></mixed-citation></ref><ref id="pone.0156381.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Gannon</surname><given-names>RH</given-names></name>, <name><surname>Millward</surname><given-names>DJ</given-names></name>, <name><surname>Brown</surname><given-names>JE</given-names></name>, <name><surname>Macdonald</surname><given-names>HM</given-names></name>, <name><surname>Lovell</surname><given-names>DP</given-names></name>, <name><surname>Frassetto</surname><given-names>LA</given-names></name>, <etal>et al</etal>
<article-title>Estimates of daily net endogenous acid production in the elderly UK population: analysis of the National Diet and Nutrition Survey (NDNS) of British adults aged 65 years and over</article-title>. <source>Br J Nutr</source>. <year>2008</year>;<volume>100</volume>(<issue>3</issue>):<fpage>615</fpage>–<lpage>23</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1017/S0007114508901240">10.1017/S0007114508901240</ext-link></comment> .<pub-id pub-id-type="pmid">18394215</pub-id></mixed-citation></ref><ref id="pone.0156381.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Filipowicz</surname><given-names>R</given-names></name>, <name><surname>Beddhu</surname><given-names>S</given-names></name>. <article-title>Optimal nutrition for predialysis chronic kidney disease</article-title>. <source>Adv Chronic Kidney Dis</source>. <year>2013</year>;<volume>20</volume>(<issue>2</issue>):<fpage>175</fpage>–<lpage>80</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1053/j.ackd.2012.12.007">10.1053/j.ackd.2012.12.007</ext-link></comment> .<pub-id pub-id-type="pmid">23439377</pub-id></mixed-citation></ref><ref id="pone.0156381.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Abramowitz</surname><given-names>MK</given-names></name>, <name><surname>Hostetter</surname><given-names>TH</given-names></name>, <name><surname>Melamed</surname><given-names>ML</given-names></name>. <article-title>Lower serum bicarbonate and a higher anion gap are associated with lower cardiorespiratory fitness in young adults</article-title>. <source>Kidney int</source>. <year>2012</year>;<volume>81</volume>(<issue>10</issue>):<fpage>1033</fpage>–<lpage>42</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ki.2011.479">10.1038/ki.2011.479</ext-link></comment> ; PubMed Central PMCID: PMC3340439.<pub-id pub-id-type="pmid">22297677</pub-id></mixed-citation></ref><ref id="pone.0156381.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Haider</surname><given-names>DG</given-names></name>, <name><surname>Lindner</surname><given-names>G</given-names></name>, <name><surname>Wolzt</surname><given-names>M</given-names></name>, <name><surname>Ahmad</surname><given-names>SS</given-names></name>, <name><surname>Sauter</surname><given-names>T</given-names></name>, <name><surname>Leichtle</surname><given-names>AB</given-names></name>, <etal>et al</etal>
<article-title>Hyperphosphatemia Is an Independent Risk Factor for Mortality in Critically Ill Patients: Results from a Cross-Sectional Study</article-title>. <source>PloS one</source>. <year>2015</year>;<volume>10</volume>(<issue>8</issue>):<fpage>e0133426</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0133426">10.1371/journal.pone.0133426</ext-link></comment> ; PubMed Central PMCID: PMC4529074.<pub-id pub-id-type="pmid">26252874</pub-id></mixed-citation></ref><ref id="pone.0156381.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Kovesdy</surname><given-names>CP</given-names></name>, <name><surname>Ahmadzadeh</surname><given-names>S</given-names></name>, <name><surname>Anderson</surname><given-names>JE</given-names></name>, <name><surname>Kalantar-Zadeh</surname><given-names>K</given-names></name>. <article-title>Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease</article-title>. <source>Kidney int</source>. <year>2008</year>;<volume>73</volume>(<issue>11</issue>):<fpage>1296</fpage>–<lpage>302</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ki.2008.64">10.1038/ki.2008.64</ext-link></comment> .<pub-id pub-id-type="pmid">18337714</pub-id></mixed-citation></ref><ref id="pone.0156381.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Rodriguez-Benot</surname><given-names>A</given-names></name>, <name><surname>Martin-Malo</surname><given-names>A</given-names></name>, <name><surname>Alvarez-Lara</surname><given-names>MA</given-names></name>, <name><surname>Rodriguez</surname><given-names>M</given-names></name>, <name><surname>Aljama</surname><given-names>P</given-names></name>. <article-title>Mild hyperphosphatemia and mortality in hemodialysis patients</article-title>. <source>Am J Kidney Dis</source>. <year>2005</year>;<volume>46</volume>(<issue>1</issue>):<fpage>68</fpage>–<lpage>77</lpage>. .<pub-id pub-id-type="pmid">15983959</pub-id></mixed-citation></ref></ref-list></back></article>